Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the Journal of Clinical Oncology (March 2, 2009).
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the Journal of Clinical Oncology (March 2, 2009).
Researchers looked at 311 patients with stable or responding disease after CVP therapy. At 2 years, an improved disease response was seen in 22% of rituximab-treated patients vs just 7% of control subjects. Toxic effects were minimal in both groups. Three-year progression-free survival was also higher in the maintenance rituximab group: 68% vs 33% in controls.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.